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Abstract
Background: Implementation of surveillance programs for at-risk populations and identification of biomarkers for
early hepatocellular carcinoma (HCC) detection are a major public health goal. Recently, osteopontin (OPN) has
attracted attention as a promising biomarker, with some potential advantages compared to alpha-fetoprotein (AFP),
but its role in the context of alcoholic cirrhosis has never been assessed. The aims of this study are to assess the
utility of plasma OPN in the diagnosis of HCC in alcoholic cirrhotic patients and to investigate whether increased
values are due to the tumor or underlying liver disease severity.
Methods: A total of 90 consecutively alcoholic cirrhosis patients, observed between Jun 2013 and May 2014 at a
Liver Disease Unit, were included and divided into two groups: 45 without (group I) and 45 with HCC (group II).
Plasma levels of OPN (ELISA, Immuno-Biological Laboratories, Gunma, Japan) and AFP (IMMULITE® 2000 AFP,
Siemens Healthcare Diagnostics, Tarrytown, New York) were assessed. The diagnostic accuracy of each marker was
evaluated using Receiver-Operating Characteristic (ROC) curve analysis (AUC) and its 95 % Confidence Interval (CI).
Results: Plasma OPN levels in group I patients (1176.28 +/–744.59 ng/mL) weren’t significantly different from those
of group II (1210.75 +/–800.60 ng/mL) (p = 0.826). OPN levels significantly increased with advancing BCLC tumor
stage and with advancing Child-Pugh class, in both groups. Comparing the two groups, AUC for OPN and AFP
were 0.51 (95 % CI: 0.39–0.63) and 0.79 (95 % CI: 0.70–0.89), respectively. Based on the ROC analysis, there were no
satisfactory cut-off values for OPN that would distinguish patients with from those without tumour.
Conclusions: Despite having a correlation with BCLC stage, the same was observed with progressive deterioration
of underlying liver function in terms of Child-Pugh class and MELD score, and isn’t a useful diagnostic biomarker for
HCC in alcoholic cirrhotic patients, particularly in the early stages. AFP confirms the performance evidenced in other
studies, being superior to OPN. Searching more specific biomarkers for early diagnosis of HCC in alcoholic cirrhosis
is still warranted.
Background
Diagnosis of hepatocellular carcinoma (HCC) has recently
increased in many low incidence countries including
Portugal [10, 16, 37]. The incidence and mortality rates
are heterogeneous, but mortality during the last decades
increased and according to World Health Organization
(WHO) has a mortality rate of about 47,000 deaths/year
in Europe, close to the rate of incidence. Early detection of
HCC opens doors for various effective treatments such as
surgical resection and transplantation, which can subse-
quently lead to long-term survivals in a greater number of
patients. Although surveillance and better diagnostic tech-
niques have improved outcomes, the overall 5 years sur-
vival rate is only 8.6 % in Europe [7, 39].
In 80–90 % of cases, HCC develops on underlying
liver cirrhosis or inflammation [21]. Worldwide, approxi-
mately 54 % of cases can be attributed to HBV infection
while 31 % can be attributed to HCV infection, leaving
approximately 15 % associated with other causes. The
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percentage of alcohol related HCCs is not well defined,
but alcoholic cirrhosis is clearly a risk factor for HCC
[15], and in one study, alcoholic liver disease accounted
for 32 % of all HCC’s [22]. In Portugal, for instance, al-
coholic cirrhosis (AC) is the most common cause of
chronic liver disease being responsible for 84 % of a total
of 81 543 hospital admissions for cirrhosis between 1993
and 2008 [31].
Implementation of surveillance programs to identify
at-risk candidate populations and identification of bio-
markers for early HCC detection are a major public
health goal to decrease HCC-related deaths. According
to the EASL–EORTC Clinical Practice Guidelines on
Management of HCC, patients with cirrhosis are at high
risk and should be enrolled in surveillance programs.
The current recommendation for HCC surveillance con-
sists of ultrasound that should be performed every
6 months in patients at high risk. This method has a
sensitivity of 60 % [9, 28], although the presence of cir-
rhosis, with fibrous septa and regenerative nodules, pro-
duce a coarse pattern which may impair identification of
small tumours. [14].
Alpha-fetoprotein (AFP) is the most widely used sero-
logical marker but has a suboptimal performance and is
considered an inadequate screening test for HCC. The
association of AFP and ultrasound significantly increases
costs and the number of false positives, seeming to have
no advantage in practice and therefore is not currently
recommended [11, 13].
Other serological biomarkers have been or are under
investigation for early diagnosis of HCC, including des-
gamma-carboxy prothrombin (DCP) (also known as pro-
thrombin induced by Vitamin K Absence II–PIVKA II),
the ratio of glycosylated AFP (L3 fraction) to total AFP,
alpha-fucosidase, and glypican 3. None of these have
better performance characteristics than AFP.
Recently osteopontin (OPN) attracted attention as a
promising biomarker for HCC diagnosis in patients with
virus related cirrhosis with better sensitivity than AFP in
differentiating HCC cases from cirrhosis controls as sug-
gested by the results of two major studies [27, 36], which
included patients with liver disease, particularly chronic
HBV or HCV infections.
Kim J and coworkers determined plasma levels of
OPN (ELISA), as well as AFP and PIVKA II, in 62 pa-
tients with HCC (69 % HBV, 10 % HCV, 3 % alcohol re-
lated), in 60 patients with chronic liver disease without
tumor (83 % HBV, HCV 3 %, 10 % alcohol related) and
in 60 healthy controls. Significantly higher plasma OPN
levels (p <0.001) where detected in patients with HCC
(median 954 ng/ml, range 168–5742) than in chronic
liver disease (381 ng/ml, 29–1688) and healthy controls
(155 ng/ml, 10–766). OPN levels correlated with pro-
gressive deterioration of underlying liver function in
terms of Child-Pugh class and advancing degree of
tumor stage. The sensitivity and specificity of OPN for
the diagnosis of HCC were 87 % and 82 %, respectively,
for a cut-off of 617.6 ng/mL. OPN had an AUC (0.898)
greater than AFP (0.745) or PIVKA II (0.578), suggesting
a better diagnostic accuracy. Immunohistochemistry
showed OPN expression of in 92 of 285 tumors (32.3 %)
and was found in malignant hepatocytes and macro-
phages, which invade the tumor, but not in normal he-
patocytes or in Kupffer cells [27].
Shang S et al. performed proteomic profiles of plasma
from patients with cirrhosis or HCC and validated se-
lected candidate HCC biomarkers in two geographically
distinct cohorts to include HCC of different etiologies.
Mass spectrometry profiling identified OPN as signifi-
cantly up-regulated in HCC cases. OPN levels were sub-
sequently measured in 312 plasma samples from 131
patients with HCC, 76 cirrhotics, 52 with chronic hepa-
titis B or C and 53 healthy controls, belonging to two in-
dependent cohorts. OPN has a higher sensitivity than
AFP in the diagnosis of HCC in all groups and was also
useful in HCC patients with normal AFP. A prospective
pilot study involving 22 patients who developed HCC
during follow-up found that OPN was already increased
one year before diagnosis, thus suggesting a potential
predictive role of this biomarker for the occurrence of
the tumor [36].
However, it is known that OPN correlates to other tu-
mors and pathological conditions, which can impose a
strong limitation to its use as a HCC marker. Indeed,
some studies have demonstrated its role in tumorigen-
esis and metastasis formation, and expression of OPN
has been detected in several types of carcinomas in
humans. Despite that, OPN is an attractive potential
tumor marker, found in the extra-cellular matrix se-
creted and also in body fluids, including plasma [25].
OPN expression is found physiological in bone and
kidney, but can also be detected in many organs in
pathological conditions. Hepatic expression of OPN was
first found in Kupffer cells, stellate cells and macro-
phages in inflammatory and necrotic areas, in rats with
carbon tetrachloride intoxication [25]. Subsequently, it
was shown to have increased expression in patients with
AC, and also in cirrhosis of other etiologies, like NASH,
primary biliary cirrhosis, autoimmune hepatitis, primary
sclerosing cholangitis, suggesting that chronic liver injury
is the main factor for the induction of OPN response [38].
Serum OPN levels are correlated with hepatic inflamma-
tion and fibrosis in heavy alcohol drinkers, and hepatic
OPN expression levels are strongly correlated with hepatic
neutrophils accumulation, the pro-fibrogenic factor TGF-
beta and fibrosis [5, 6, 19, 33].
Circulating levels of OPN are elevated in patients with
liver lesions associated with HCV and HBV infections.
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For example, higher levels were an excellent indicator of
cirrhosis in patients with chronic hepatitis B [40] and
correlated with liver fibrosis in chronic hepatitis C, as
found by Huang W et al. [23].
Although data suggests a better performance of
plasma OPN in the diagnosis of HCC, the role of this
biomarker needs validation. Moreover, data are lacking
in alcoholic liver disease (only 2 in 62 patients with
HCC have alcoholic cirrhosis in the study of Kim J
et al.), the most common risk factor of HCC among us.
So we conducted a study with the following objectives:
(1) evaluate the usefulness of plasma OPN in the diagno-
sis of HCC in patients with alcoholic cirrhosis, and com-
pare its accuracy with AFP; (2) investigate whether
increased OPN is due to the tumor or underlying dis-
ease; and determine if there is any relationship between
plasma OPN levels and the activity or severity of liver
disease.
Patients and methods
Patients and plasma samples
This study was performed with approval from the Ethics
Committee of the Faculty of Medicine of the University
of Coimbra, and written informed consent was obtained
from each patient. Patients followed between Jun 2013
and May 2014 at the Liver Disease Unit–Internal Medi-
cine Department and Hepatic Transplantation Unit at
Coimbra Hospital and University Centre were included.
A total of 90 consecutively observed patients with AC
were included and divided into two groups: group I in-
cluded 45 patients with AC, and group II included 45
patients with AC and HCC.
The diagnosis of AC was established on the basis of
clinical, laboratory, imaging (ultrasonography and com-
puted tomography), transient elastography and histo-
logical examinations, as needed. All patients had a
history of alcohol intake >60 g/day for more than
10 years and other causes of liver disease (HBV, HCV,
autoimmune and metabolic diseases) were excluded.
Status of liver function was defined as grades A, B or
C based on the Child-Pugh classification [20] and
Model for End-stage Liver Disease (MELD) Score was
calculated [24].
The diagnosis of HCC was based according to the
non invasive criteria of EASL–EORTC Clinical Practice
Guidelines on Management of HCC. Tumor status,
liver function and health status (ECOG) were obtained
and patients were divided in stages (0, A, B, C and D)
according to the Barcelona Clinic Liver Cancer (BCLC)
staging system [12].
In all the subjects, blood was collected in a plastic tube
containing ethylene diamine tetra acetic acid (EDTA),
and isolated plasma and serum samples were stored at–
80 °C until measurements of OPN and AFP levels. All
measurements were performed at Immunology Unit of
the same institution.
Measurement of plasma OPN level
Plasma OPN levels were measured using an enzyme-
linked immune sorbent assay (ELISA) kit (human osteo-
pontin assay kit, Immuno-Biological Laboratories, Gunma,
Japan) according to the manufacturer’s instructions. This
ELISA kit measures total concentration of both phosphor-
ylated and nonphosphorylated forms of OPN in plasma.
All the experiments were performed in duplicate.
Measurement of serum AFP Level
Serum AFP levels were measured with the same sample
by the chemiluminescence method using IMMULITE®
2000 AFP kit (Siemens Healthcare Diagnostics, Tarrytown,
New York) according to the manufacturer’s instructions.
Statistical analysis
Median, range, mean, and standard deviation were used for
descriptive statistics, as appropriate. Categorical variables
were tested with Fisher’s exact test or χ 2 test. Continuous
variables were tested with Student t-test. Comparison of
plasma OPN and AFP levels and clinical characteristics
among the two groups of subjects were analyzed using the
Mann–Whitney U test and Kruskal-Wallis test. Correlation
between plasma levels of OPN and AFP were analyzed
using Spearman’s correlation coefficient. Receiver operating
characteristics (ROC) analysis was used to evaluate the
diagnostic value of OPN, AFP, and to identify the optimal
threshold values. p-value <0.05 was considered statistically
significant.
Results
The demographics, functional status of liver in terms of
Child-Pugh class, MELD score, and tumor stage of the
subject patients are summarized in Table 1.
AFP and OPN levels in patients with and without HCC
AFP and OPN levels in patients with and without
HCC, and the distribution according to clinical features
(Child-Pugh class and BCLC stage) are presented on
Tables 2 and 3. AFP levels were significantly higher in
cirrhotic patients with HCC than in those without
HCC (p-value <0.001), but the same was not found with
OPN, with no difference between groups (p-value = 0.826).
Plasma OPN levels were progressively increased and are
correlated with the degree of deterioration of func-
tional liver status in terms of advanced Child-Pugh
(Spearman rho [ρ] value of 0.533; p-value <0.001) and MELD
score (Spearman rho [ρ] value of 0.518; p-value <0.001),
but the same was observed regardless of the presence or
absence of HCC as shown in Fig. 1. AFP serum levels
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were not correlated with the Child-Pugh class (ρ = 0.001;
p-value = 0.990). Both OPN and AFP levels were signifi-
cantly increased with advancing BCLC tumor staging.
When we compared cirrhotic patients of group I with
early stages of HCC (BCLC stages 0 and A), we found no
difference between the two as determined by Mann–
Whitney U test (p-value = 0.353).
ROC analysis of OPN and AFP levels in patients with and
without HCC
Receiver operating characteristic (ROC) curves compar-
ing for OPN and AFP are shown in Fig. 2. When HCC
patients were compared to non HCC patients, the area
under curve (AUC) for OPN (0.51; 95 % CI: 0.39–0.63)
was lower than that of AFP (0.79; 95 % CI: 0.70–0.89),
suggesting a non superior accuracy to AFP for the diag-
nosis of HCC. The sensitivity and specificity of AFP
levels in HCC relative to AC group were 57.8 % and
93.3 %, respectively, at a cut-off value of 8.2 ng/mL
(similar to the cut-off value recommended by manufac-
turer’s instructions). Based on the ROC analysis, there
were no satisfactory cut-off values for OPN that would
best distinguish HCC from non HCC patients.
Discussion
In most published papers [3, 8, 27, 34–36] OPN showed
an advantage over AFP in the diagnosis of HCC in pa-
tients with cirrhosis due to HBV or HCV infections,
with the best performance obtained by combining OPN
and AFP [36].
However, other studies published after the start of
our work, have not confirm its usefulness in this con-
text [1, 26] and until now there are no published data
on the value of OPN in the diagnosis of HCC in pa-
tients with alcoholic liver cirrhosis. To our knowledge
this is the first study of the role of OPN in this etiology
of chronic liver disease.
In our study, plasma OPN levels were not significantly
different between cirrhotic patients with and without
HCC, with an AUC of 0.51 (95 % CI: 0.39 to 0.63),
showing no significance as a diagnostic marker for the
tumor.
The OPN value range and units are diverse in different
studies, possibly due to the different techniques used.
Kim J et al. used the same reference kits and the OPN
values were of the same order of magnitude (average in
the HCC group of 946.3 ng/mL and 964.0 ng/mL, re-
spectively, in our patients and Kim J et al.).
OPN levels correlated with progressive deterioration
of underlying liver function in terms of Child-Pugh class
and MELD score in both groups, suggesting a correl-
ation with clinical severity of liver disease. This favors
the hypothesis that OPN is a protein with multiple func-
tions implicated in hepatic inflammation and fibrosis,
and could be a relevant biomarker for significant liver fi-
brosis [19, 33], but in our cohort all patients have liver
cirrhosis and we do not have assessed OPN levels from
individuals with non-cirrhotic alcoholic liver disease or
from healthy subjects, so we cannot conclude about its
use as a biomarker of fibrosis.
The difference between results of OPN in the chronic
liver disease (CLD) group in the study of Kim J et al.
Table 1 Clinical characteristics of cirrhotic patients with and
without hepatocellular carcinoma (HCC)
Group I Group II p-value*
(Cirrhosis) (Cirrhosis and HCC)
N (%) 45 (50.0 %) 45 (50.0 %)
Age 58.68 ± 10.76 64.64 ± 7.73 0.003
Sex (F/M) (1/49) (0/50)
Child-Pugh class 0.052
A 20 (44.4 %) 21 (45.6 %)
B 8 (17.8 %) 16 (35.6 %)
C 17 (37.8 %) 8 (17.8 %)
MELD scorea 14.04 ± 5.56 12.71 ± 4.25 0.205
BCLC Stageb
0 2 (4.4 %)
A 19 (42.2 %)
B 11 (24.4 %)
C 7 (15.6 %)
D 6 (13.3 %)
*p - Value was calculated by using Student T test or χ2 test
aModel for End-stage Liver Disease score
bBarcelona Clinic Liver Cancer
Table 2 Serum levels of alpha-fetoprotein (AFP) in cirrhotic
patients with and without HCC, and the relation to clinical
features (Child-Pugh class and BCLC stage)
AFP (ng/mL) Group I Group II p-value
(Cirrhosis) (Cirrhosis and HCC)
3.00 (0.90-17.00) 11.00 (1.30-431272.00) <0.001*
Child-Pugh class 0.627 **
A 2.50 (1.10-13.00) 10.00 (1.30-2159.00)
B 3.40 (1.10-5.60) 14.00 (1.60-431272.00)
C 3.10 (0.90-17.00) 12.45 (1.40-8251.00)






*p - Value by Mann–Whitney U test for comparison of serum AFP between
two groups
**p - Value by Kruskal-Wallis test for comparison of serum AFP across Child-Pugh
classes and BCLC stages
aBarcelona Clinic Liver Cancer
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(median 381 ng/mL; limits: 29–1688) and our (median:
946.30 ng/mL; limits: from 337.10 to 3583.00) may be due
to the fact that they had only 50 % of cirrhosis in the CLD
group, while in our case, all the patients had cirrhosis (and
thus greater severity of liver disease). It is possible, of
course, that the cause of CLD may also influence the
plasma levels of OPN; in our study all patients were alco-
holic, while in Kim J et al. only 10 % had this etiology.
In Group II we found a direct correlation of OPN with
HCC BCLC stage, but our patients with early tumors
Table 3 Serum levels of osteopontin (OPN) in cirrhotic patients with and without HCC, and the relation to clinical features (Child
Pugh class and BCLC stage)
OPN (ng/mL) Group I Group II p-value
(Cirrhosis) (Cirrhosis and HCC)
923.80 (193.80-2786.20) 946.30 (337.10-3583.00) 0.826*
Child-Pugh class <0.001**
A 534.95 (193.80-1778.60) 742.30 (337.10-2593.80)
B 1051.85 (384.20-2786.20) 1017.80 (502.40-2775.10)







*p-value by Mann–Whitney U test for comparison of plasma OPN between two group
**p-value by Kruskal-Wallis test for comparison of serum OPN across Child-Pugh classes and BCLC stages
aBarcelona Clinic Liver Cancer
Fig. 1 Plasma osteopontin (OPN) levels according to Child-Pugh class in patients with cirrhosis (Group I) and cirrhosis with hepatocellular carcinoma
(Group II). Box refers to the 25th and 75th percentile values, with a line indicating median levels, whereas the interquartile range extends outside the box.
Points outside the interquartile range are outliers. The plasma OPN level was progressively increased according to the Child-Pugh class in both groups
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(stages 0 and A), corresponding to 46.6 % of Group II
patients, had average OPN values lower than that ob-
served in Group I patients. Our data also shown that in
alcoholic liver disease the amount of OPN is associated
mainly with the severity of cirrhosis, and therefore could
mask the increase that would occur due to the presence
of HCC.
As already demonstrated in alcoholic patients, OPN
correlates with hepatic inflammation, infiltration of neu-
trophils (alcoholic hepatitis), fibrosis and TGF-beta ex-
pression [19, 33]. In our patients we cannot prove that
inflammation contributes significantly to the values of
OPN, because none had clinical or analytical changes
suggesting alcoholic hepatitis or other acute inflamma-
tory process. However, we cannot categorically rule out
this hypothesis, since we have no histological data from
the time when blood draws for the OPN assays were
collected.
According to the literature, the specificity of AFP for
the diagnosis of HCC varies between 76 % and 96 %, be-
ing improved by raising the cut-off value, which in turn
decreases sensitivity [18, 29]. AFP performance in our
population was similar, with an AUC of 0.791 (95 % CI:
0.697 to 0.885), and sensitivity and specificity of, 55.6 %
and 93.3 % respectively, for a cut-off 8.6 ng/ml (normal
laboratory reference). Increasing the cut-off value to
23.5 ng/mL results in a specificity of 100 %, but a de-
crease in sensitivity to only 42.2 %.
A positive correlation between AFP serum levels and
the stage of the tumor was shown in many studies
[2, 17, 30, 32]. Similarly, in our patients we found the
same correlation when we compared the serum AFP
values with BCLC tumor stage. Moreover, AFP results
were not influenced by the severity of liver cirrhosis,
assessed by Child-Pugh score.
As previously said, we do not have histological data
from the time when blood draws for OPN assays were
collected, and in fact we only have liver biopsy in 26 pa-
tients (28,9 %), which is a limitation of our study and
that’s why we could not exclude accompanying inflam-
matory processes, which deserves further research aimed
to better characterize the role of alcoholic liver disease
on the plasma levels of OPN. Another limitation was the
sample size, as suggested by the wide range of OPN
levels detected among patients with early stages of HCC
patients. Although other causes of liver disease such as
NAFLD or NASH were excluded, OPN levels are also
increased in patients with type 2 diabetes, metabolic syn-
drome, obesity and smokers, but we cannot exclude
these confounding factors since this was beyond the
scope of the study and we haven’t performed this ana-
lysis. Finally, OPN is subject to alternative splicing as
Fig. 2 Receiver operating characteristics (ROC) curve for OPN (AUC = 0,51) and for AFP (AUC = 0,79)
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well as post-translational modifications, such as phos-
phorylation, glycosylation and proteolytic cleavage, and
functional differences have been revealed for different
isoforms and post-translational modifications. The pattern
of isoform expression and post-translational modification
is cell-type specific and may influence the potential role of
OPN in malignancy and as a cancer biomarker, and some
studies have reported that cleaved OPN may exhibit a bet-
ter correlation with disease stage [4]. We used an ELISA
kit that measures total concentration of both phosphory-
lated and nonphosphorylated forms of OPN in plasma,
which can be a limitation of our study.
Conclusions
In summary, the results of this study show that:
– OPN is not a suitable marker for HCC diagnosis in
patients with liver cirrhosis of alcoholic etiology;
– In AC, OPN values increase with disease severity,
regardless of the presence of HCC;
– In early stages of HCC (0 and A of BCLC
classification) OPN value is lower than in patients
without tumor, supporting the idea that the severity
of cirrhosis is the cause of increased OPN in our
population;
– In our patients, AFP confirms the performance
evidenced in other studies, showing not to be the
ideal marker, although being better than OPN.
These results confirm the lack of uselessness of tumor
markers in HCC early diagnosis and reinforce the import-
ance of radiological methods in the surveillance of risk
groups, requiring, however, to be done by trained radiolo-
gists and proper equipment.
Finally, we emphasize that it is essential to continue re-
search looking for new biomarkers, particularly important
in AFP negative cases.
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